METHODS IN COMPLEMENTARY/ALTERNATIVE MEDICINE & HIV/AIDS

描述（改编自申请人摘要） 单独的纵向观测数据集将产生初步数据 关于临床、实验室和生活质量（QOL）健康结局 与补充和替代医学（CAM）的使用相关 艾滋病毒阳性男性和女性的治疗。这两个国家的数据收集工作都已结束 研究，只有完成数据管理，数据验证和分析 被提议。这两项研究旨在筛选最常用的 通过比较CAM治疗的结果与 另一种是同时进行抗病毒药物治疗。主 两项研究的结果变量均为CD 4 + T淋巴细胞、HIV-1 外周血水平、体重指数、HIV健康状况量表 医疗结果调查、临床艾滋病进展率和存活率。 次要结果变量是与疾病相关的发病率和患病率。 症状与诊断这两项研究是：I）替代医疗护理 1995年10月至1997年10月期间入组了1689名HIV阳性患者的艾滋病结局（AMCOA）研究 全国范围内被确定为使用CAM疗法治疗艾滋病毒的男性和女性 疾病1998年10月之前，每半年收集一次数据， 每一位参与者的岁月生存期的进一步验证和完成 AMCOA研究中的分析取决于对死亡的计划分析。2)约翰 霍普金斯和巴斯蒂尔合作研究了与CAM使用相关的结果， 入组多中心AIDS队列研究（MACS）的受试者， 对HIV阳性男性的观察性研究。90%的MACS参与者报告说， 第26次和第27次半年度访问，了解他们使用35种替代品中的任何一种 在过去的6个月里接受治疗，允许健康状况在一个月内发生变化 年之间进行比较的治疗方案。尽管这两项研究使用了 有些不同的方法，他们的一些结果可以比较， 确定一项研究中的重大发现是否反映了 其他.该中心正在寻求资金，以完成对AMCOA和 Bastyr-Johns霍普金斯MACS研究。

DESCRIPTION (Adapted from the applicant's abstract) The analysis of two separate longitudinal observational datasets will generate preliminary data about Clinical, laboratory, and quality of life (QOL) health outcomes associated with the use of complementary and alternative medical (CAM) therapies in HIV+ men and women. Data collection has ended in both of these studies, and only completion of data management, data validation and analysis are proposed. The two studies were designed to screen the most frequently used treatments for benefit or harm by comparing outcomes of CAM treatments with one another and with concurrent pharmaceutical anti-viral therapy. The primary outcome variables for both studies were changes in CD4+ T lymphocytes, HIV-1 peripheral blood levels, body mass index, the health status scales of the HIV Medical Outcomes Survey, progression rate to clinical AIDS, and survival rates. Secondary outcome variables are the incidence and prevalence of disease related symptoms and diagnoses. The two studies are: I) the Alternative Medical Care Outcomes in AIDS (AMCOA) study which during 10/95 to 10/97 enrolled 1689 HIV+ men and women nationwide who were identified as using CAM therapies for HIV disease. Data were collected until October 1998 semi-annually for up to two years on each participant. Further validation and completion of the survival analysis in the AMCOA study depends on a planned analysis of deaths. 2) Johns Hopkins and Bastyr collaborated in studying outcomes associated with CAM use in subjects enrolled in the Multicenter AIDS Cohort Study (MACS), a 14 year observational study of HIV+ men. 90% of the MACS participants reported at their 26th and 27th semi-annual visits about their use of any of 35 alternative treatments in the preceding 6 months, allowing health status changes over one year to be compared among treatment options. Though the two studies used somewhat different methodologies, some results from them can be compared to determine if significant findings in one study demonstrate a reflection in the other. The Center is seeking funding to complete analysis of both the AMCOA and Bastyr-Johns Hopkins MACS studies.